Blueprint Medicines (BPMC) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key growth drivers and commercial performance

• Ayvakit launch in indolent systemic mastocytosis (ISM) is showing strong growth, with peak sales projected north of $2 billion and guidance raised twice this year to $435–$450 million.

• Large and expanding diagnosed patient pool, with over 21,000 diagnosed in the U.S. and increasing breadth and depth of physician prescribing.

• High patient compliance, long duration of therapy, and smooth reimbursement processes are supporting sustained revenue growth.

• International expansion, especially in Europe, is progressing well, with Germany leading ISM launches and pricing negotiations ongoing.

• Seasonal impacts and pricing adjustments are being considered for future guidance, but overall conviction in long-term growth remains high.

Clinical and patient impact

• Ayvakit addresses a high unmet need in ISM, providing transformational benefits and improving quality of life beyond clinical measures.

• Duration of therapy is expected to be multi-year, with trends suggesting even longer use in ISM compared to advanced SM.

• Physicians are increasingly treating a broader spectrum of ISM patients, including those with milder symptoms, due to the disease's progressive nature.

• Claims data show an 18–20% progression rate from ISM to advanced SM, highlighting the need for early and root-cause treatment.

Pipeline and R&D strategy

• Elenestinib, a next-generation KIT D816V inhibitor, is being advanced with a differentiated development strategy, with registrational work starting by year-end.

• BLU-808, a wild-type KIT inhibitor, is in phase I healthy volunteer studies, with data expected early next year and chronic urticaria as the lead indication.

• BLU-808 aims to modulate mast cell activity in allergic and inflammatory disorders, leveraging Blueprint’s expertise in KIT inhibition.

• BLU-222, a selective CDK2 inhibitor, is being developed for hormone-positive, HER2-negative breast cancer, with ongoing partnering discussions and a degrader program in progress.

• The R&D engine is focused on innovation in allergy, inflammation, and oncology, including targeted protein degradation.